Life sciences and biotech £86bn boost to science and tech in the UK to turbocharge economy £86bn to fund everything from new drug treatments and longer-lasting batteries to new AI breakthroughs to generate billions for the UK economy and drive our Plan for Change Latest Content Siemens acquires Dotmatics Elsevier launches ScienceDirect AI to transform research Elsevier introduces Embase AI New technologies Solution Accelerators for biotech research Merz consolidates its R&D with a Life Sciences platform White papers Standardization of Analytical Data: Best Practices Standardization is critical to extracting the full potential of data. This White Paper offers a comprehensive guide to overcoming challenges and driving progress in analytical chemistry and beyond. Advancing the use of emerging computing infrastructure in Life Sciences RCH Solutions supports the adoption of novel computing technologies such as cloud, quantum, AI and edge computing paradigms through a co Boosting productivity of monoclonal antibody development using Chromeleon CDS: A collaboration to move biopharma forward Using the right tools is of paramount importance in the effort to advance tomorrow’s therapies. Webcasts On Demand Webinar: Consolidating computing resources can democratise research infrastructure More content Pocket-sized DNA sequencers track malaria drug resistance in near real-time Atos and WWF aim to automate biodiversity surveillance Neo4j announces a collaboration with AWS to address AI hallucinations Pistoia Alliance sets out its strategy to accelerate sustainability and the adoption of AI Which computing innovators made this year's Photonics100? Case study: Via Nova Therapeutics uses CDD Vault to support global collaboration Advancing bioscience research with machine learning Understanding infection with machine learning 2023 State of Tech in Biopharma report reveals tech strategies in era of data and AI Ganymede Bio and Kytopen to bring cloud-native structured data to gene-modified cell therapy Collaboration aims to facilitate regenerative cell therapy product development Uncovering the mechanisms underlying lack of response to immunotherapy Pagination Previous page ‹ Previous Page 10 Next page Next ›
